|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2013
|
|
gptkbp:ATCCode
|
gptkb:J05AP08
|
|
gptkbp:bioavailability
|
~92%
|
|
gptkbp:CASNumber
|
1190307-88-0
|
|
gptkbp:category
|
gptkb:antiviral_drug
gptkb:nucleotide
gptkb:prodrug
|
|
gptkbp:contraindication
|
hypersensitivity to sofosbuvir
|
|
gptkbp:drugInteraction
|
gptkb:phenytoin
gptkb:rifampin
gptkb:carbamazepine
gptkb:St._John's_Wort
|
|
gptkbp:halfLife
|
0.4 hours (sofosbuvir), 27 hours (GS-331007 metabolite)
|
|
gptkbp:hasEliminationRoute
|
renal
|
|
gptkbp:hasInChIKey
|
YYOQXSRSLFDYER-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C22H29FN3O9P
|
|
gptkbp:hasPatent
|
US8076328B2
|
|
gptkbp:hasSMILES
|
CC(C)COC(=O)[C@H](NC(=O)[C@@H]1O[C@](C#N)(CO)[C@@H](O)[C@H]1O)P(=O)(OCC2=CC=CC=C2)O
|
|
gptkbp:indication
|
treatment of hepatitis C
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Gilead_Sciences
|
|
gptkbp:mechanismOfAction
|
NS5B RNA polymerase inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
529.45 g/mol
|
|
gptkbp:name
|
gptkb:Sofosbuvir
|
|
gptkbp:pregnancyCategory
|
B1 (AU), not assigned (US)
|
|
gptkbp:PubChem_CID
|
gptkb:DB08908
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
fatigue
headache
insomnia
|
|
gptkbp:status
|
true
|
|
gptkbp:synonym
|
gptkb:Sovaldi
gptkb:GS-7977
gptkb:PSI-7977
|
|
gptkbp:target
|
NS5B polymerase
|
|
gptkbp:bfsParent
|
gptkb:dimethyl_fumarate
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB08908
|